Theranostic radionuclides: recent advances in production methodologies

Qaim, S.M.

doi:10.1007/s10967-019-06797-y

Cited by 56 publications

(29 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Me-DO2PA (Fig. 5D), a [12]aneN4 bearing two picolinic acid arms and two methylcapped amines has also been reported to be stable in vivo when radiolabeled with 213 Bi [69,70]. Even though DOTA-derivatives have shown promising results as 213 Bi chelators, other options have been explored.…”

Section: Dota and Dota-derivativesmentioning

confidence: 99%

“…It is also important to mention here that theranostic approach could also involve a solitary radionuclide agent -this theory stipulates the use of a solitary radionuclide, producing both a therapeutic radiation and a low-energy γ-ray for SPECT measurements to deliver dosimetric data. Examples of some of these radionuclides are 47 Sc (T½ = 3.35 d) and 67 Cu (T½ = 2.58 d) [12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

Ahenkorah¹,

Cassells²,

Deroose³

et al. 2021

Preprint

View full text Add to dashboard Cite

Besides external high-energy photon or proton beam therapy, targeted radionuclide therapy (TRNT) is an alternative approach to deliver radiation to cancer cells. TRNT is distributed within the body by the vascular system and allows targeted irradiation of a primary tumor and all its metastases, resulting in substantially less collateral damage to normal tissues as compared to ex-ternal beam radiotherapy (EBRT). It is a systemic cancer therapy, tackling systemic spread of the disease, which is the cause of death in most cancer patients. The α-emitting radionuclide bis-muth-213 (213Bi) has interesting properties and can be considered as a magic bullet for TRNT. The benefits and drawbacks of targeted alpha therapy with 213Bi are discussed in this review, covering the entire chain from radionuclide production to bedside. First, the radionuclide properties and production of 225Ac and its daughter 213Bi are discussed, followed by the fundamental chemical properties of bismuth. Next, an overview of available acyclic and macrocyclic bifunctional chelators for bismuth, and general considerations for designing a 213Bi-radiopharmaceutical are provided. Finally, we will provide an overview of preclinical and clinical studies involving 213Bi-radiopharmaceuticals, as well as the future perspectives of this promising cancer treatment option.

show abstract

Section: Dota and Dota-derivativesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

Ahenkorah¹,

Cassells²,

Deroose³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…In particular, a 30 or 40 MeVd(Be) or d(C) breakup neutron source is considered to be suitable for the production of a few radionuclides via the (n,p) or (n,np) reaction [43]. The estimated integral cross sections amount to a few mb [5]. The spallation neutrons also appear to be interesting for the formation of a few radionuclides [44].…”

Section: Current Nuclear Data Activitiesmentioning

confidence: 99%

“…The positron emitters are generally produced at small-sized cyclotrons, the number of which worldwide is now increasing to about 1200 [3]. Attempts are presently also underway to produce several therapeutic radionuclides at cyclotrons/accelerators, using either the charged particle beam or secondary radiation, that is, neutrons and photons, generated at accelerators (for recent reviews, cf [4,5]). Nuclear data play a continuing role in the development of radionuclides for applications.…”

Section: Introductionmentioning

confidence: 99%

Continuing Nuclear Data Research for Production of Accelerator-Based Novel Radionuclides for Medical Use: A Mini-Review

et al. 2021

Self Cite

View full text Add to dashboard Cite

Nuclear data are important for production and medical application of a radionuclide. This brief review concentrates on nuclear reaction cross-section data. The availability of standardized nuclear data for accelerator-based production of medical radionuclides is outlined. Some new directions in radionuclide applications, for example, theranostic approach, bimodal imaging, and radionuclide targeted therapy, are considered and the status of relevant nuclear data is discussed. The current trends in nuclear data research using accelerators are elaborated. The increasing significance of intermediate energy accelerators in production of therapeutic radionuclides is emphasized.

show abstract

“…radiometals with similar properties (starting with indispensable comparable half-lives), ideally from the same element, and exhibiting diagnostic and therapeutic properties. The theranostic match pairs 68 Ga/ 177 Lu, 68 Ga/ 90 Y, 64 Cu/ 67 Cu, 86 Y/ 90 Y, 43,44 Sc/ 47 Sc and 149,152 Tb/ 149,155,161 Tb, among others, have been used in clinical applications to date (Cutler et al 2013;Qaim 2019;Qaim et al 2018). In certain cases, a single radionuclide can present both properties as is the case for 64 Cu (both β + and βdecays) and 149 Tb (both β + and α decays).…”

Section: Introductionmentioning

confidence: 99%

Production of radiometals in liquid targets

Carmo

Scott

Alves

2020

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Over the last several years, the use of radiometals has gained increasing relevance in supporting the continuous development of new, complementary and more specific biological targeting agents. Radiopharmaceuticals labelled with radiometals from elements such as Tc, Zr, Y, Ga and Cu received increasing attention as they find application in both diagnostic SPECT and PET imaging techniques and radiotherapeutic purposes. Such interest stems from the wide variety of radionuclides available with distinct and complementary nuclear decay characteristics to choose from with unequalled specificity, but can also be explained by growing demand in targeted radionuclide therapy. As a result, as routine supply of these radiometals becomes mandatory, studies describing their production processes have expanded rapidly. Although most radiometals are traditionally provided by the irradiation of solid targets in specialized cyclotrons, recently developed techniques for producing radiometals through the irradiation of liquid targets have received growing attention due to compatibility with commonly available small medical cyclotrons, promising characteristics and encouraging results. Irradiating liquid targets to produce radiometals appears as a fast, reliable, convenient and costefficient alternative to the conventional solid target techniques, characterized by complex and time-consuming pre-and post-irradiation target handling. Production of radiometals in liquid targets incorporated to complete manufacturing processes for daily routine is already recognized as a viable alternative and complementary supply methodology to existing solid target based infrastructures to satisfy growing clinical demands. For instance, several sites already use the approach to produce 68 Ga-radiopharmaceuticals for clinical use. This review article covers the production of common radiometals with clinical potential through the irradiation liquid targets. A comparison with the traditional solid target irradiation methods is presented when relevant.

show abstract

Theranostic radionuclides: recent advances in production methodologies

Cited by 56 publications

References 64 publications

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

Continuing Nuclear Data Research for Production of Accelerator-Based Novel Radionuclides for Medical Use: A Mini-Review

Production of radiometals in liquid targets

Contact Info

Product

Resources

About